MedPath

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

Phase 3
Not yet recruiting
Conditions
Preimplantation Genetic Testing
Progestin-primed Ovarian Stimulation
Polycystic Ovarian Syndrome
GnRH Antagonist
Interventions
Registration Number
NCT05326087
Lead Sponsor
ShangHai Ji Ai Genetics & IVF Institute
Brief Summary

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:

Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.

PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.

The primary outcome is the euploidy rate of blastocysts.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
204
Inclusion Criteria
  • Women age between 20 and 37 years.
  • Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume >10 mL on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded
Exclusion Criteria
  • Presence of a functional ovarian cyst with E2>100 pg/mL
  • Endometriosis grade 3 or higher
  • Repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success)
  • Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
  • Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;
  • Recipient of oocyte donation
  • Presence of hydrosalpinx which is not surgically treated

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Antagonist groupGnRH antagonistWomen will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
PPOS groupMPAWomen will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger.
Primary Outcome Measures
NameTimeMethod
euploidy rate1 month after oocyte retrieval

euploidy rate of blastocysts

Secondary Outcome Measures
NameTimeMethod
birthweight of newborns1 year after embryo transfer

birthweight of newborns

ongoing pregnancy12 weeks' gestation

a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer

OHSS(ovarian hyperstimulation syndrome)1 month after ovarian stimulation

Moderate or severe ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome (OHSS) is diagnosed and classified according to the Royal College of Obstetricians and Gynaecologists guideline.

Green-top guideline No.5. Ovarian hyperstimulation syndrome. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/ (accessed 26 Feb 2016).

cumulative live birth rate1 year after embryo transfer

cumulative live birth within 6 months of randomization

live birth rate1 year after embryo transfer

deliveries ≥22 weeks gestation with heartbeat and breath of the first frozen embryo transfer

number of oocytes retrieved1 day after oocyte retrieval

number of oocytes retrieved

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.